#	Pagina
attuale pagina	/open-h2020/projects/223934/index.html
-1	/open-h2020/projects/219077/index.html
-2	/open-h2020/projects/197367/results.html
-3	/open-h2020/projects/197914/index.html
-4	/open-h2020/projects/213460/index.html
-5	/open-h2020/projects/220040/index.html
-6	/open-h2020/projects/224201/index.html
-7	/open-fp7/projects/103223/index.html
-8	/open-h2020/projects/223301/index.html
-9	/open-h2020/projects/217784/index.html
-10	/open-fp7/projects/188168/index.html

Opendata, web and dolomites

LASER-HEAL

A breakthrough laser-based medical device to eradicate bacterial biofilm in chronic wounds and accelerate wound healing.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

LASER-HEAL project word cloud

Explore the words cloud of the LASER-HEAL project. It provides you a very rough idea of what is the project "LASER-HEAL" about.

silent care cumulative cells global mins preliminary biofilms deep million wound wounds total recognize antibiofilm standard consists manner backed time solution people first 10m smei showing protecting skin generating truly commercialize 12 bn income changing abstract market compatible acquisition markets bacteria killing optomechatronics clinics solutions introduction map session regulatory exit seek sales informa game left species company obtaining contours 39bn software 2025 fda intact laser 29bn pay move 75 willingness approval fast tackle de confidential annual gt epidemic safe confirm rapid risked device human commercial proposition revenue invasive eradicate delivering predicted medical 22 heal chronic 2024 lack 72bn treatment 2017 data preferred successful

Project "LASER-HEAL" data sheet

The following table provides information about the project.

Coordinator	VULCUR MEDTECH Organization address address: SONDERVIGVEJ 50 city: VANLOSE postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	http://vulcur.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-05-01 to 2019-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VULCUR MEDTECH VULCUR MEDTECH Organization address address: SONDERVIGVEJ 50 city: VANLOSE postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (VANLOSE)	coordinator	50˙000.00

Map

Project objective

Chronic wounds affect 10M in Europe and 6.4 million people in the US, with annual costs of >€72Bn in Europe and >€22 Bn in the US. It is a silent epidemic. Key to this problem is the lack of truly effective solutions that fully eradicate bacteria-protecting biofilms deep within chronic wounds.

We have a game-changing new solution to tackle this problem: LASER-HEAL. LASER-HEAL is a medical device that consists of 1) a laser-generating unit that can reach deep within wounds; 2) optomechatronics to move the laser in a controlled manner and 3) software to recognize the contours and depth of wounds. LASER-HEAL enables, for the first time, non-invasive, safe, low-cost (€1.000 p/treatment), rapid (30 mins/session, total ~12) treatment, compatible with standard of care. We have preliminary data showing killing of all relevant species of bacteria, while human skin cells are left intact.

We will bring LASER-HEAL to the global wound care management market (€29bn in 2017 expected to reach €39bn by 2024). We will respond to the need of this market by delivering an effective antibiofilm device for chronic wounds. We will commercialize LASER-HEAL through sales to US clinics first, through fast FDA approval and confirm willingness to pay. By 2025, we will demonstrate revenue potential for LASER-HEAL, and seek a commercial exit, through acquisition (preferred) by a major medical device company, who will then bring LASER-HEAL to the European and global markets. Cumulative income of €75 million is predicted for LASER-HEAL by 2025 during this phase.

We have a unique proposition, backed by preliminary results and the interest of a major wound care company (confidential for this abstract). We want to undertake a detailed study to map successful market introduction for LASER-HEAL. Funding from SMEi Phase can support us with obtaining crucial market, regulatory and de-risked development informa

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LASER-HEAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LASER-HEAL" are provided by the European Opendata Portal: CORDIS opendata.